Drug
Photopheresis
Photopheresis is a pharmaceutical drug with 5 clinical trials. Historical success rate of 75.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(20%)
Phase Distribution
Ph not_applicable
2
40%
Ph phase_1
1
20%
Ph phase_2
2
40%
Phase Distribution
1
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
2(40.0%)
N/ANon-phased studies
2(40.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(3)
Terminated(1)
Other(1)
Detailed Status
Completed3
Terminated1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (20.0%)
Phase 22 (40.0%)
N/A2 (40.0%)
Trials by Status
terminated120%
unknown120%
completed360%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
NCT00045305
completedphase_2
Photopheresis for the Treatment of Acute Graft Versus Host Disease
NCT00609609
unknownnot_applicable
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
NCT03500575
terminatednot_applicable
Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation
NCT00502554
completedphase_1
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
NCT00306969
Clinical Trials (5)
Showing 5 of 5 trials
NCT00045305Phase 2
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
NCT00609609Phase 2
Photopheresis for the Treatment of Acute Graft Versus Host Disease
NCT03500575Not Applicable
Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients
NCT00502554Not Applicable
Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome (BOS) After Lung Transplantation
NCT00306969Phase 1
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5